We explored changes in the survival of patients with AIDS (PWA) according to the availability of antiretroviral drugs (1994 Á 2002). We tested whether changes in the hazard ratio of progression to death (HR) have been homogeneous among various groups of PWA. We included 4158 PWA diagnosed in Paris, notified to the French National Surveillance Institute by 2002. Four calendar periods were defined: monotherapy (1994 Á95), bitherapy-HAART transition (1996), early HAART (1997 Á 99), late HAART (2000 ÁOctober 2002. HR were calculated with Cox models, including the calendar period, modelled as a time dependent covariate. Models were stratified by age, transmission category, CD4 cell count, and AIDS-defining illnesses (ADI) group. Cumulative survival at 60 months increased from 44.0% (before July 1996) to 75.6% (after July 1996) and median survival increased from 31.9 months to 76 months. Adjusted HR reached a minimum in the late HAART period (HR 0.22, 95% CI: 0.19 Á0.26). No difference in the decrease of the HR has been found by age. HR decreased and was marked during the late HAART period across all HIV transmission categories, including intravenous drug use. HR decreased significantly for all ADIs groups, including tumours. Among PWA diagnosed with tuberculosis, the HR decreased significantly only in the late HAART period. HR decrease was stronger for PWA with a CD4 cell count 5200/mm 3 . Substantial improvements in survival after the introduction of HAART were found for all PWA but varied by specific ADIs and the degree of immunosuppression.
Introduction
The beneficial effects of highly active antiretroviral therapy (HAART), increasing survival and preventing the development of an AIDS-defining illness, are well established (Palella et al., 1998; Mocroft et al., 2000) . A large increase in the survival of HIVinfected patients has been demonstrated in industrialized countries, in controlled trials (Hammer et al., 1997) , studies on cohorts of patients with HIV (Detels et al., 1998; Porter et al., 2003; Sterne et al., 2005; Schneider et al. 2005; Tassie et al., 2002; Wong et al., 2004) , and studies based on AIDS case reporting in Europe (Conti et al., 2000; Rogers et al., 2000) , the United States (Fordyce et al., 2002; Schwarcz et al., 2000) , Australia (Dore et al., 2002) , and Brazil (Marins et al., 2003) .
Recent studies have demonstrated the sustained beneficial long-term effect of HAART in PWA (Schneider et al. 2005; Sterne et al., 2005) .
However, no population-based study has characterized changing survival patterns after AIDS through the evolution of antiretroviral therapies with a long follow-up time of more than 8 years. Furthermore, since the introduction of HAART, no recent study based on AIDS population surveillance has assessed heterogeneity in the hazard ratio of progression to death according to AIDS-defining illness (ADI), type of transmission, or CD4 cell count at AIDS diagnosis.
Further population-based studies that provide more generalizable epidemiological data on the long-term efficacy of HAART are required.
Therefore, in this population-based surveillance study, we aimed to explore changes in the survival of PWA according to time of diagnosis and calendar period, used as markers of changes in the availability of antiretroviral therapies from 1994 to 2002. We investigated whether changes in the hazard ratio of progression to death were homogeneous in the various subgroups of PWA.
Methods

AIDS case surveillance
In France, the notification of AIDS cases has been mandatory since 1986 and AIDS is defined on the basis of clinical conditions, according to the 1993 European AIDS case definition. This definition differs from the definition used in the USA in that it does not include CD4 cell count criteria (Ancelle-Park et al., 1993) .
All AIDS cases are reported to the French National Surveillance Institute (Institut de Veille Sanitaire [InVS] ). The underreporting of AIDS cases has been estimated at less than 15% (Bernillon et al., 2000) , and more than 90% of reported AIDS cases are notified within 12 months of diagnosis. Duplicate cases are detected with a specific programme and deleted from the database.
Inclusion criteria
The study included all 4229 PWA over the age of 15 years first diagnosed with AIDS at one of the 12 major Paris hospitals from 1 January 1994 to 31 December 2001 and reported to the InVS by 31 December 2002, to take into account notification delay. The 12 hospitals selected were those where more than 100 AIDS cases were diagnosed between 1994 and 2001.
End-point and mortality
We considered the probability of progression to death after AIDS diagnosis by the study end-point, 31 October 2002. We included deaths from all causes. In France, the deaths of PWA, whatever the cause of death, must be notified to the InVS by clinicians. However, deaths after AIDS diagnosis are known to be underreported (Bernillon et al., 2000) . We therefore carried out two successive, preliminary surveys to determine the vital status of all 2770 PWA not reported dead at the end-point. First, we carried out an active survey, from February to March 2003, in which we reviewed medical records in all the participating hospitals. Second, for the 901 PWA whose vital status remained unknown on 31 October 2002, we matched AIDS cases and the French national registry for the identification of physical persons (a national register of births and deaths), in September 2003, to identify patients who had died (Inserm., 2006) . In France, deaths are monitored by means of death certificates, which must be filed with this register within one week of death.
Variable definition
For each PWA, we recorded sociodemographic characteristics and data concerning HIV infection. Antiretroviral therapy before AIDS diagnosis was defined as antiretroviral therapy for at least three months in the two years preceding AIDS diagnosis. AIDS cases in which HIV infection was diagnosed less than three months before AIDS were classified as 'late' HIV diagnosis, whereas cases in which HIV infection was diagnosed at least three months before AIDS were classified as 'early' HIV diagnosis.
The period of AIDS diagnosis was defined according to protease inhibitor (PI) availability: pre-HAART period (from 1 January 1994 to 30 June 1996), and HAART period (1 July 1996 to 31 December 2001).
The AIDS case reporting system provides no information about individual treatment. Data on the proportion of PWA receiving HAART at least once in the year were obtained for the treated PWA followed up at the 12 study hospitals from the French Hospital Database on HIV (FHDH). Based on these data, we defined four calendar periods, taking into account changes in the availability of new antiretroviral therapies at population level. The reference period selected for this study ran from 1994 through 1995, when monotherapy (mostly zidovudine) was used. Bitherapy (combination of two nucleoside analogs), replaced monotherapy around the end of 1995, although a few patients included in clinical trials began to receive this treatment earlier. We defined 1996 as a period of transition from bitherapy to HAART. The first protease inhibitors (PIs) (indinavir, ritonavir and saquinavir) became widely available in France, following their full authorization for market release, in the second half of 1996. The early HAART period ran from 1997 through 1999 and the late HAART period ran from 2000 through October 2002. The proportion of PWA treated with HAART during each calendar period was as follow: 0% (monotherapy), 45% (bitherapy-HAART transition), 75% (early HAART) and 75% (late HAART period).
Statistical analysis
Survival time was calculated in months from the date of AIDS diagnosis to the censoring date using the Kaplan-Meier method.
Censoring date was defined as the earliest date of the following events: 1) if the PWA was known to be alive at the endpoint of the study, 31 October 2002; 2) if the PWA was lost to follow-up, the date of the last medical visit; 3) if the PWA died, the date of death. Death from any cause was the outcome variable considered. PWA defined as 'lost to follow-up' were those not known to have died and for whom a censoring date was available before the end point. PWA for whom no vital status information after AIDS diagnosis was available or for whom the date of death was unknown were excluded from the analysis. Mortality rates were calculated as the number of deaths per 100 person-years of exposure. Personyears was the sum total of the length of time (in years) each PWA has been exposed to a period. Univariate analysis was performed using the log-rank test to examine the influence on progression to death of 9 variables: sex, age group, country of birth, socioprofessional category, transmission category, antiretroviral therapy before AIDS diagnosis, CD4 cell count at AIDS diagnosis, HIV diagnosis, ADI.
To estimate the HR of progression to death according to calendar period, we used a Cox proportional hazards model in which calendar period was modelled as a time-dependent covariate so that for each individual, data for each 'time period' he/she had been at risk were analysed. With this model, we were able to compare the risk of death during a given period with that for the calendar period of reference (monotherapy), taking the other variables into account.
Variables with a p value less than 0.2 in the univariate analysis were included in the multivariate model.
We assessed changes in the HR of progression to death for the various subgroups by modelling the relationship between survival and calendar period with separate proportional hazard models stratified by age group, transmission category, CD4 cell count, and ADI group.
All models were adjusted for the hospital at which diagnosis was made, to control for the design effect. We used the Stata 7 † software package (Stata Corporation, College Station, Texas, USA) for statistical analyses.
Results
Population description and increase in survival
Between 1 January 1994 and 31 December 2001, the 4229 AIDS cases of the original sample accounted for more than 70% of all 5985 PWA diagnosed in Paris during the study period. Of these 4229 cases, 71 (2%) were excluded.
The analysis included 4158 PWA, 1695 of whom (40.8%) had died with a known date of death, 1981 (47.6%) of whom were still alive on 31 October 2002 and 482 (11.6%) of whom were lost to followup with a censoring date.
The PWA lost to follow-up (n 0482) were more likely than those not lost to follow-up (n 03676) to be female, younger, infected by heterosexual activity and born in Sub-Saharan Africa. Pulmonary and extrapulmonary tuberculosis was also more frequent among the PWA lost to follow-up.
Mean CD4 cell count at AIDS diagnosis increased from 89.9/mm 3 (95% CI: 83.9 Á96.0), for PWA diagnosed during the pre-HAART period, to 129.3/ mm 3 (95% CI: 121.3 Á137.3, p B0.001) for those diagnosed during the HAART period (Table I) . In treated PWA, mean CD4 cell count at AIDS diagnosis did not differ significantly according to the period of AIDS diagnosis.
The proportion of patients with Kaposi's sarcoma, cytomegalovirus disease and cryptosporidiasis decreased significantly during the HAART period, whereas the proportion of patients with brain toxoplasmosis, tuberculosis and non Hodgkin lymphoma increased (Table II) .
Cumulative survival at 24 months and 60 months increased from 54.8% (95% CI: 52.7 Á56.9) and 44.0% (95% CI: 41.9 Á46.1), respectively, for PWA diagnosed during the pre-HAART period to 82.9% (95% CI: 81.1 Á84.7) and 75.6% (95% CI: 73.2 Á 77.8) for those diagnosed in the HAART period.
Median survival increased from 31.9 months (95% CI: 28.4 Á39.7) in the pre-HAART period to over 76 months in the HAART period.
Hazard ratio of progression to death as a function of calendar period between 1994 and October 2002
Mortality rate was 57.9/100 person-years (PY)(95% CI: 53.6-62.6) during the period of monotherapy, 38.8/100 PY (95% CI: 35.2 Á42.9) during the bitherapy-HAART transition period, and 23.7/100 PY (95% CI: 21.5 Á26.1) and 7.1/100 PY (CI: 6.3 Á 7.9) for the early and late HAART periods, respectively (Figure 1. and Table III ).
The covariate HIV diagnosis was not introduced in the multivariate analysis due to its colinearity with antiretroviral therapy before AIDS diagnosis (data not shown).
The HR of progression to death began to decline in the bitherapy-HAART transition and continued to decrease into the late HAART period, with the period of monotherapy used as a reference (Table III) .
The decrease in the HR of progression to death did not differ according to transmission category (Table IV) . The decrease in the HR of death in PWA with CD4 cell counts over 200/mm 3 , was statistically significant in the late HAART period. For PWA with CD4 cell counts 5200/mm 3 , this decrease began to tail off in 1996 (period of transition from bitherapy to HAART), with the monotherapy period used as a reference.
The decrease in the HR of death was marked for all ADI groups. This difference was significant only in the late HAART period for those with pulmonary or extrapulmonary tuberculosis. HR of deaths for HIV wasting syndrome or multiple ADIs and progressive multifocal leukoencephalopathy or AIDS dementia only began to significantly decrease from early HAART period and the decrease for tumours was significant in the transition period but not in the early HAART period, possibly due to a lack of power.
Discussion
This study shows that there was a rapid, large increase in the survival of PWA diagnosed in Paris following the introduction of HAART. Furthermore, survival continued to improve in the late HAART calendar period (2000ÁOctober 2002, adjusted HR Our study has several limitations. First, our estimates of the risk of progression to death are probably sensitive to event ascertainment and loss to follow-up. As in normal practice for survival studies, we used last date of medical visit as a censoring date for those patients not known to have died. Observational bias due to these patients being lost to follow-up may have affected our results. However, more than 88% of PWA were not lost to follow-up. Furthermore, the PWA who were lost to follow-up were more likely to be younger, infected by heterosexual activity and diagnosed with tuberculosis. These factors are known to be associated with improved survival (Conti et al., 2000; Dore et al., 2002; Fordyce et al., 2002) . Antiretroviral therapy is free in France, so patients will not remain untreated for economic reasons. Assuming that all PWA who were lost to follow-up had access to HAART, survival may therefore have been at the most underestimated in our study (Del Amo et al., 1998; Lot et al., 2004; Staehelin et al., 2004) .
Second, we did not adjust for time-dependent confounders for the effect of HAART such as CD4 cell count (Barron et al., 2004; Cole et al., 2005) . Patients with lower CD4 cell counts are more likely to be treated and CD4 cell count is also affected by HAART. In this situation, a type of confounding by indication, our analysis may have partially biased estimates of the effects of the calendar period (Cole et al., 2005) . However, due to the study design, it was not feasible to have detailed collection of CD4 cell counts. Furthermore, we analysed the risk of progression to death by calendar period modelled as a time dependent variable: this method may have reduced confounding by indication under the assumption that HAART was the only variable responsible for changes in prognosis over time (Sterne et al., 2005) .
Third, one possible bias, described as survivor selection bias is that patients who live longer are more likely to receive HAART, so that any treatment effect may actually reflect only the selection of longterm survivors. Adjustment for the length of time of infection which may have controlled for this selection bias was not feasible in our study because of the lack of such data through AIDS notifications. However, we attempted to control for this bias by including calendar period as a timedependent covariate which is a standard method of preventing such bias (Glesby et al., 1996) . Finally, the study may have lacked power to detect changes in the HR of progression to death in selected subgroups of PWA by calendar period.
Despite these limitations, one of the strengths of this study is that it was a real population-based study. Hence, our population accounted for more than 70% of all PWA diagnosed in Paris. It included not only PWA who were followed in the participating hospitals but also those (901 cases) who were not followed in the hospitals anymore and for whom active surveys were carried out to determine their vital status. Therefore, we believe our sample was representative of the whole population of PWA diagnosed in Paris hospitals between 1994 and 2001.
Population survival and changes in survival for various subgroups
The major decrease in the risk of progression to death is consistent with previous reports based on AIDS surveillance data from industrialized countries and data from observational studies (Palella et al., 1998; Fordyce et al., 2002; Dore et al., 2002; Sterne et al., 2005; Schneider et al., 2005) .
In a previous study conducted in the same hospitals, with similar methods, from 1981 to 1993, when only monotherapy was prescribed, the cumulative survival rate at 24 months was 35.3% (Semaille et al., 1997) . In our study, conducted after 1994, cumulative survival rate at 24 months increased from 54.8% for PWA diagnosed during the pre-HAART period to 82.9% for those diagnosed during the HAART period.
To our knowledge, there are few reports on median survival time after AIDS in the HAART era. Hence, the improved prognosis associated with treatment advances is often expressed in relative terms, such as percentages reduction in AIDSrelated mortality, rather than more absolute terms, such as median survival time after AIDS. One Australian study reported a median survival time of 39.6 months for PWA diagnosed in between 1996 and 2000 (Dore et al., 2002) and another study estimated the median survival time of over 70 months for those diagnosed between 1996 and mid-2003 (Wong et al., 2004) . Our finding of a median survival time of over 76 months would need to be confirmed. However, direct comparisons of median survival time are difficult because of several factors, including population variations, and different analysis and treatment strategies or access; in our study, the proportion of PWA presenting with tuberculosis that is less likely to be fatal than other opportunistic infections (Conti et al., 2000; Fordyce et al., 2002) was much higher than in the Australian study.
The decline in the HR of progression to death began in 1996, following the introduction of bitherapy, and became particularly marked following the introduction of PIs. The continuing decrease in mortality rates in the late HAART calendar period may be related to greater experience with HAART and availability of new drugs, improvements in the understanding and management of complicated drug regimens and toxicities, and of the role of drug resistance (Mocroft et al., 2003) . The advent of simpler regimens and new therapies such as efavirenz, abacavir, tenofovir and lopinavir with favourable safety profiles and lower pill burdens may also have improved long-term compliance and subsequent survival (Maggiolo et al., 2002; Stones et al., 2004) , reflected in the marked decrease in the HR of progression to death during the late HAART period.
The HR of progression to death decreased markedly during the last period for all HIV transmission categories. Even if intravenous drug users have an excess mortality risk over their population peers related to their drug use (Vlahov et al., 2004) , we found that their HR of progression to death decreased over calendar periods, similarly to homosexual and heterosexual transmission groups. However, other studies from Italy, Spain or Switzerland found that the effect of HAART may be less beneficial in intravenous drug users compared with other transmission groups due to less access to HAART and less adherence (Dorrucci et al., 1999; Perez-Hoyos et al., 2003; Sterne et al., 2005) . Possible consideration for the improved survival observed in our study is the increased access and evolving readiness for HAART that is effective in intravenous drug users (Celentano et al., 2001; Vlahov et al., 2005) . However, clinicians may have been somewhat reluctant to provide treatment to this population because of concerns about adherence to HAART. Other factors other than therapy may have influenced survival such as better uptake and compliance with various health interventions (Moatti et al., 2000) . Therefore, our study does not prove that treating all intravenous drug users will produce levels of treatment efficacy similar to those seen for PWA of other transmission categories. Nonetheless, our results demonstrate the importance of not excluding PWA from treatment on the basis of their demographic or HIV risk group.
There was also a decrease in the HR of progression to death for all ADIs, including progressive multifocal leukoencephalopathy, HIV dementia and tumours. In contradiction with previous populationbased studies with shorter follow-up time (Conti et al., 2000; Dore et al., 2002) , our findings suggest that HAART may have an impact on the mortality of PWA with tumours. The immune recovery induced by HAART increases tolerance to chemotherapy, thereby improving the efficacy of anti-cancer treatment (Holkova et al., 2001; Hoffmann et al., 2003; Heard et al., 2002) .
The effect of calendar period differed according to ADI. The HR of progression to death rapidly decreased in those with an infectious opportunist infection. The HR of death decreased later, and to a lesser extent in PWA who had tuberculosis, suggesting that HAART had a delayed effect. This may have resulted from greater difficulties in obtaining access to medical care, due to the difficult social situations of these patients (Bates et al., 2004; Holtgrave et al. 2004) . The later prescription of HAART because of the paradoxical worsening of tuberculosis following early antiretroviral therapy may also account for these results (Breen et al., 2005) . Another explanation of the lower effect of HAART on PWA with tuberculosis is probably that they already had a long survival due to the fact that tuberculosis often develops before deep immunosuppression. As well, HAART has a lower impact on immune restoration when a CD4 cell count is high; this was observed for PWA with CD4 cell counts over 200 CD4/mm 3 in our study.
As survival has continued to increase in PWA since the introduction of HAART, cardiovascular diseases (Friis-Moller et al., 2003) , and the risk of emergence of HIV resistance to HAART may not have affected mortality during the early and late HAART periods.
Our analysis stopped in 2002 and recent data on mortality causes show an increase in cardiovascular diseases which may impair longer-term survival (Sackoff et al., 2006) . Therefore, longer follow-up of cohorts with a known duration of HIV infection is required to determine whether there has been a persistent levelling off of the decrease in mortality rates.
